ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Surviv...( SAN DIEGO June 16 /- ADVENTRX Pha...),Health

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic colorectal cancer. Overall survival results in this study have been revised upwards slightly, with the CoFactor/5-FU (5-fluorouracil) arm demonstrating a 14 day improvement in overall survival compared to the leucovorin/5-FU arm.

"In the Phase 2b study, CoFactor was dosed at 60mg/m2 by infusion to provide as unbiased a comparison as possible to leucovorin, which is administered at 200 mg/m2 by infusion over about 2 hours in this setting," stated Evan M. Levine, Chief Executive Officer and President of ADVENTRX. "Even while administering CoFactor over hours instead of the more optimal 2 to 3 minute bolus administration, and at a significantly lower dose of the folate, we were able to demonstrate a numerical advantage with respect to overall survival and progression-free survival with CoFactor plus 5-FU in this study, which is encouraging."

Consistent with its previous guidance, the Company anticipates announcing available interim data from its discontinued Phase 3 trial of CoFactor for the treatment of first line metastatic colorectal cancer later this month. Furthermore, the Company is on track to announce its decision about how to best move forward with its CoFactor program later this month.

About the CoFactor Phase 2b Study

The Phase 2b clinical trial was an international, open-label, randomized, controlled, multicenter study designed to evaluate the safety and efficacy of treatment with CoFactor/5-FU compared to leucovorin/5-FU utilizing an infusional administration in patients wi
'/>"/>